Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: Results of the GO-FORTH study

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 817-824

  Tanaka, Yoshiya ^a   Harigai, Masayoshi ^b   Takeuchi, Tsutomu ^c   Yamanaka, Hisashi ^d   Ishiguro, Naoki ^e   Yamamoto, Kazuhiko ^f   Miyasaka, Nobuyuki ^b   Koike, Takao ^g   Kanazawa, Minoru ^h   Oba, Takuya ⁱ   Yoshinari, Toru ^j   Baker, Daniel ^k  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NTT CORPORATION   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ Janssen Pharmaceutical KK   (Japan)

^j MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^k JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO;

ADULT; AGED; ANAPHYLAXIS; ANTERIOR CRUCIATE LIGAMENT INJURY; AORTA DISSECTION; ARTICLE; BONE TUMOR; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEMANGIOENDOTHELIOMA; HERPES ZOSTER; HUMAN; HUMERUS FRACTURE; HYPERTENSION; ILEUS; INFECTION; INJECTION SITE REACTION; INTERVERTEBRAL DISK HERNIA; JAPANESE; JOINT RADIOGRAPHY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SERUM SICKNESS; SKIN DISEASE; TENDON RUPTURE; TUBERCULOSIS;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84860908371     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.200317     Document Type: Article

References (21)

1. Herman S, Krönke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008;14:245-53.
2. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74. (Pubitemid 350180008)
3. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010;2:428-39.
4. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
5. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
6. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
7. Ling J, Lyn S, Xu Z, et al. Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol 2010;50:792-802.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
9. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
10. Siegel JN, Zhen B-G. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005;52:1637-41. (Pubitemid 40852869)
11. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
12. van Riel PL, van Gestel AM, Scott DL. EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications BV; 2000:1-55.
13. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
14. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
15. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75. (Pubitemid 351563997)
16. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
17. Visvanathan S, Rahman MU, Keystone E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 2010;12:R211.
18. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46:328-46.
19. Seto Y, Tanaka E, Inoue E, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. doi:10.1007/s10165-011-0445-4 (In Press).
20. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15:280-94. (Pubitemid 39423287)
21. Vila AT, Puig L, Fernández-Figueras MT, et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 2005;153:417-23. (Pubitemid 41228444)